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To the Editor, 
 
We read with interest the recent article by Giannone et al. where the use of ischaemia-
modified albumin (IMA) as a molecular marker of bacterial infection in patients with cirrhosis 
was assessed [1]. IMA corresponds to a “modified” form of albumin that exhibits reduced 
ability to bind Co2+ (with its presence associated with certain medical conditions, including 
ischaemia). The study revealed a positive correlation between circulating IMA levels and 
infection in the examined cohort, suggesting that IMA may be a useful marker for screening 
and monitoring infection in subjects with cirrhosis. Although these findings are indeed 
interesting, the authors perpetuate a previously held belief that IMA is a modified form of 
albumin oxidised at the N-terminus, a known binding site for Cu2+ and Ni2+ ions.  
 
Recent evidence suggests strongly that the basis of IMA is unlikely to be oxidative 
modification at the N-terminus. It has been shown that plasma IMA levels and N-terminal 
albumin modification (as probed using N-terminally-directed antibodies) do not correlate in 
acute coronary syndrome [2]. Also rapid clearance of IMA, observed within hours of an 
ischaemic event, is incompatible with serum albumin’s 19-day circulating half-life [3]. 
Moreover, the N-terminus is not a preferred Co2+-binding site on albumin [4]. Such findings, 
together with the observation that elevated plasma free fatty acid (FFA) levels are 
associated with disease states where high IMA levels are observed (see [5]), led us to 
examine whether IMA may be FFA-loaded albumin. The effects of FFAs on Co2+ binding to 
albumin were examined in vitro, where it was found that physiologically relevant 
concentrations of the long-chain FFA myristate reduced the Co2+-binding affinity and 
capacity of albumin at two sites [5], known as sites A and B, which are preferred binding 
sites for Co2+ [4]. This also resulted in a corresponding increase in measured “IMA” using the 
standard albumin-cobalt binding assay [5].  
 
These observations have important implications for the study by Giannone et al., as it 
appears that IMA is strictly speaking neither a marker for oxidative stress nor infection but 
more likely a proxy measurement of plasma FFA levels. Given that the authors discuss the 
basis of their results exclusively in the context of covalent albumin modifications (which in 
light of current evidence are unlikely origins for IMA), a re-evaluation of their data 
considering potential changes in FFA metabolism within their cohort may provide a more 
consistent explanation for the reported findings. 
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